Bringing the Oncology Community Together

Study Finds Role for Maintenance Bevacizumab in mCRC

Ben Leach
Published Online: Wednesday, January 16, 2013
bevacizumab (Avastin)A combination of maintenance bevacizumab (Avastin) plus standard second-line chemotherapy appears to be an effective strategy in managing patients with metastatic colorectal cancer (mCRC) after disease progression, according to the results of a phase III trial reported in Lancet.1

The open-label, multicenter study involved 820 patients with unresectable mCRC whose disease progressed within three months after discontinuing firstline bevacizumab plus chemotherapy. They were randomized to receive bevacizumab 2.5 mg/kg per week equivalent (either 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks, intravenously). plus second-line chemotherapy (n = 409) or chemotherapy alone (n = 411).

In this study, if a patient received oxaliplatin-based chemotherapy in the first-line setting, he received irinotecan-based chemotherapy in the second-line setting, and vice versa. The primary endpoint was overall survival (OS), analyzed by intention to treat.

The study found that the median overall survival (OS) in the bevacizumab combination arm was 11.2 months (95% CI, 10.4–12.2) and 9.8 months (95% CI, 8.9–10.7) in the chemotherapy-alone arm (HR = 0.81; 95% CI, 0.69– 0.94; unstratified log-rank test P = .0062). The median progression-free survival (PFS) was 5.7 months (95% CI, 5.2–6.2) in the bevacizumab arm and 4.1 months (95% CI, 3.7–4.4) in the chemotherapy-alone arm (HR = 0.68; 95% CI, 0.59–0.78; unstratified log rank P < .0001).

The grade 3-5 adverse events that were more common in the bevacizumab combination arm versus the chemotherapy-alone group were, respectively, bleeding or hemorrhage (8 [2%] vs 1 [<1%]), gastrointestinal perforation (7 [2%] vs 3 [<1%]), and venous thromboembolism (19 [5%] vs 12 [3%]). The most frequently reported grade 3-5 adverse events in the bevacizumab combination versus chemotherapy-alone group were, respectively, neutropenia (65 [16%] vs 52 [13%]), diarrhea (40 [10%] vs 34 [8%]), and asthenia (23 [6%] vs 17 [4%]). The authors noted that the safety profile of the bevacizumab and chemotherapy combination was consistent with previously reported data in bevacizumab-naïve patients, and there were not substantial differences in toxicity between the two groups in this study.

“The results from this study could serve as proof of principle that maintaining angiogenesis inhibition while switching chemotherapy from the first and second lines in colorectal cancer has clinical benefits in patients,” the authors wrote.

The FDA approved bevacizumab as a first-line treatment for mCRC in 2004 and expanded the indication two years later to include second-line therapy in combination with 5-fluorouracil-based chemotherapy.
1. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [published online ahead of print November 16, 2012]. Lancet. doi:10.1016/S1470-2045(12)70477-1.


Related Articles
Treatment of Unresectable RAS Wild-type Metastatic CRC
Panelists discuss the frontline treatment of patients with unresectable metastatic colorectal cancer, which has become a more challenging decision in recent years as a result of studies focused on RAS mutations.
Upfront Bevacizumab and Cetuximab Compared in mCRC
In this segment, Alan P. Venook, MD, discusses the ongoing comparisons between the VEGF inhibitor bevacizumab and the EGFR inhibitor cetuximab for the treatment of patients with metastatic colorectal cancer.
FDA Panel Unanimously Recommends New DNA Stool Test
The FDA’s Molecular and Clinical Genetics advisory committee has unanimously supported the safety, efficacy, and positive risk-benefit profile of the noninvasive stool-based DNA test Cologuard in a 10-0 vote.
FDA Panel Narrowly Supports New CRC Blood Test
The blood-based colorectal cancer (CRC) screening test Epi proColon passed the scrutiny of the FDA’s Molecular and Clinical Genetics advisory panel in a close 5-4 vote with 1 abstention in support of the claim that the test’s benefits outweigh its risks
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.